ALAS2
5-aminolevulinate synthase, erythroid-specific, mitochondrial
Also known as: ALAS-E, ASB, HEM0_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P22557
- Gene
- ALAS2
- Ensembl
- ENSG00000158578
- Chromosome
- X
- Canonical length
- 587 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The product of this gene specifies an erythroid-specific mitochondrially located enzyme. The encoded protein catalyzes the first step in the heme biosynthetic pathway. Defects in this gene cause X-linked pyridoxine-responsive sideroblastic anemia. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
587 residues, UniProt reviewed canonical sequence.
>P22557|ALAS2
1 MVTAAMLLQC CPVLARGPTS LLGKVVKTHQ FLFGIGRCPI LATQGPNCSQ IHLKATKAGG
61 DSPSWAKGHC PFMLSELQDG KSKIVQKAAP EVQEDVKAFK TDLPSSLVSV SLRKPFSGPQ
121 EQEQISGKVT HLIQNNMPGN YVFSYDQFFR DKIMEKKQDH TYRVFKTVNR WADAYPFAQH
181 FSEASVASKD VSVWCSNDYL GMSRHPQVLQ ATQETLQRHG AGAGGTRNIS GTSKFHVELE
241 QELAELHQKD SALLFSSCFV ANDSTLFTLA KILPGCEIYS DAGNHASMIQ GIRNSGAAKF
301 VFRHNDPDHL KKLLEKSNPK IPKIVAFETV HSMDGAICPL EELCDVSHQY GALTFVDEVH
361 AVGLYGSRGA GIGERDGIMH KIDIISGTLG KAFGCVGGYI ASTRDLVDMV RSYAAGFIFT
421 TSLPPMVLSG ALESVRLLKG EEGQALRRAH QRNVKHMRQL LMDRGLPVIP CPSHIIPIRV
481 GNAALNSKLC DLLLSKHGIY VQAINYPTVP RGEELLRLAP SPHHSPQMME DFVEKLLLAW
541 TAVGLPLQDV SVAACNFCRR PVHFELMSEW ERSYFGNMGP QYVTTYALocalizationUniProt · AlphaFold · HPA
Whether an antibody against ALAS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 571 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 571 nTPM
- placenta: 42 nTPM
- spleen: 25 nTPM
- tongue: 17 nTPM
- lung: 5.4 nTPM
- liver: 3.4 nTPM
Single-cell type
- erythrocytes: 1,762 nCPM
- erythrocyte progenitors: 375 nCPM
- hematopoietic stem cells: 3.4 nCPM
- cholangiocytes: 3.3 nCPM
- megakaryocyte-erythroid progenitors: 1.9 nCPM
- cdc: 1.3 nCPM
Immune cell
- total PBMC: 5.9 nTPM
- plasmacytoid DC: 1.6 nTPM
- MAIT T-cell: 0.2 nTPM
- memory B-cell: 0.2 nTPM
- neutrophil: 0.2 nTPM
- gdT-cell: 0.1 nTPM
Brain region
- cerebral cortex: 3.9 nTPM
- choroid plexus: 3.1 nTPM
- medulla oblongata: 3.1 nTPM
- spinal cord: 2.9 nTPM
- pons: 2.8 nTPM
- midbrain: 2.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ALAS2.
Disease | AllUniProt
Conditions ALAS2 is implicated in, by any mechanism.
- Anemia, sideroblastic, 1 (SIDBA1) MIM:300751
- Erythropoietic protoporphyria, X-linked dominant (XLDPT) MIM:300752
Disease | GeneticClinVar
50 pathogenic / likely-pathogenic of 415 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- X-linked sideroblastic anemia 1
- X-linked erythropoietic protoporphyria
- Sideroblastic anemia 1, late-onset
- See cases
- ALAS2-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.18
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.37
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- erythrocyte development
- erythrocyte differentiation
- heme B biosynthetic process
- heme biosynthetic process
- hemoglobin biosynthetic process
- intracellular iron ion homeostasis
- intracellular oxygen homeostasis
- protoporphyrinogen IX biosynthetic process
- response to hypoxia
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminotransferase, class-II, pyridoxal-phosphate binding site
- Aminotransferase, class I/classII, large domain
- Tetrapyrrole biosynthesis, 5-aminolevulinic acid synthase
- 5-aminolevulinate synthase presequence
- Pyridoxal phosphate-dependent transferase, major domain
- Pyridoxal phosphate-dependent transferase, small domain
- Pyridoxal phosphate-dependent transferase
- 8-amino-7-oxononanoate synthase class-II
- Aminotransferase class I and II
- 5-aminolevulinate synthase presequence
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ALAS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ALAS2 as an antibody target. Whether an autoantibody or antibody against ALAS2 could matter depends on whether native ALAS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ALAS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ALAS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...